Ursprung des Netzwerks ersten Grades von Inez de Greef-van der Sand
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
DegenRx BV
 DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020.
1
| Holding Company | Biotechnology | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Inez de Greef-van der Sand
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Avantium Technologies BV
 Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Miscellaneous Commercial Services | Chief Operating Officer | |
DSM Biologics Holding, Inc.
 DSM Biologics Holding, Inc. BiotechnologyHealth Technology Part of DSM-Firmenich AG, DSM Biologics Holding, Inc. is a Canadian company that manufactures biological and pharmaceutical products. The private company is based in Montréal, Canada. The company was founded by Jos van Weperen. DSM Biologics Holding was acquired by DSM Pharmaceuticals, Inc., a subsidiary of DSM-Firmenich AG from Province of Québec on July 13, 2005. | Biotechnology | Corporate Officer/Principal | |
| University of Utrecht | College/University | Graduate Degree | |
Crossbeta Biosciences BV
 Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | Biotechnology | Chief Executive Officer |
Statistik
International
| Niederlande | 4 |
| Kanada | 2 |
Sektoral
| Health Technology | 3 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 2 |
| Chief Operating Officer | 1 |
| Graduate Degree | 1 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Guus Scheefhals | 5 |
- Börse
- Insiders
- Inez de Greef-van der Sand
- Unternehmensverbindungen
